Drugs / Mesenchymal Stromal Stem Cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06012604 | Sep 2023 → Aug 2025 | — | Institute of Oncology Ljubljana | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03478215 | Dec 2016 → Dec 2025 overdue | — | The Methodist Hospital Research Institute | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mesenchymal stromal stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06012604 ↗ |
| Known as | MSC | “The aim of the study is to assess the safety and preliminary efficacy of treating xerostomia with allogeneic mesenchymal stromal stem cells (MSC) derived from umbilical cord tissue.” NCT06012604 ↗ |
| Modality | Cell therapy | “autologous mesenchymal stromal cells” NCT03478215 ↗ |
| Route | Intravenous | “administered intravenously at surgery and day 4 post-transplant” NCT03478215 ↗ |